Effect of hemodialysis on plasma myeloperoxidase activity in end stage renal disease patients

Indian Journal of Clinical Biochemistry

Volumn 27, Issue 3, 2012, Pages 253-258

  Rao, A Madhusudhana ^a   Apoorva, R ^a   Anand, Usha ^a   Anand, C V ^a   Venu, G ^a  

^a PSG INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

Author keywords

ESRD; Hemodialysis; Hemodialysis vintage; Myeloperoxidase; Oxidative stress

Indexed keywords

FREE RADICAL; MALONALDEHYDE; MYELOPEROXIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; END STAGE LIVER DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; OXIDATIVE STRESS; REGRESSION ANALYSIS; SCHOOL CHILD; SPECTROPHOTOMETRY; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 84864492629     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-012-0194-y     Document Type: Article

References (21)

1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659-63.
2. Himmelfarb J. Hemodialysis complications. Am J Kidney Dis. 2005;45:1122-31.
3. Arnhold J. Properties, functions, and secretion of human myeloperoxidase. Biochemistry. 2003;69:4-9.
4. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102-11.
5. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-604.
6. Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem. 2011;57:1-7.
7. Bansal V, Cunanan J, Hoppensteadt D, Wahi R, Fareed J. Up regulation of myeloperoxidase in end stage renal disease and its modulation by hemodialysis. J Thromb Haemost. 2007;52:S609.
8. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:59-68.
9. Wu CC, Chen JS, Wu WM, et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 2005;20:1134-9.
10. Madhusudhana Rao A, Anand U, Anand CV. Myeloperoxidase in chronic kidney disease. Indian J Clin Biochem. 2011;26:28-31.
11. Krueger AJ, Yang JJ, Roy TA, Robbins DJ, Mackerer CR. An automated myeloperoxidase assay. Clin Chem. 1990;36:158.
12. Wilbur KM, Bernheim F, Shapiro OW. The TBARS reagent as a test for the oxidation of unsaturated fatty acids by various agents. Arch Biochem Biophys. 1943;24:305-13.
13. Krieter DH, Lemke HD, Wanner C. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible membranes. Nephrol Dial Transplant. 2006;21:546.
14. Rutgers A, Heeringa P, Kooman JP, et al. Peripheral blood myeloperoxidase activity increases during hemodialysis. Kidney Int. 2003;64:760.
15. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin. Am J Kidney Dis. 2006;47:37-41.
16. Gritters M, Grooteman MPC, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant. 2006;21:153-9.
17. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-38.
18. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant. 2001;16:335-40.
19. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106: 2212-7.
20. Capeillere BC, Gausson V, Nguyen AT, Descamps LB, Drueke T, Witko SV. Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol Dial Transplant. 2006;21: 1555-63.
21. Hawkins CL, Davies MJ. Hypochlorite-induced oxidation of proteins in plasma: formation of chloramines and nitrogen-centered radicals and their role in protein fragmentation. Biochem J. 1999;340:539-48.